Patents Issued in February 15, 2018
-
Publication number: 20180043014Abstract: The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.Type: ApplicationFiled: June 20, 2017Publication date: February 15, 2018Inventors: Michael E. Jeffers, William J. LaRochelle
-
Publication number: 20180043015Abstract: Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. In an exemplary embodiment of a noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy of the present disclosure, the method comprises the steps of withdrawing at least one biological sample from a cardiac allograft recipient; and analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature; wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for or developing cardiac allograft vasculopathy.Type: ApplicationFiled: October 20, 2017Publication date: February 15, 2018Applicant: 3DT Holdings, LLCInventors: Ghassan S. Kassab, Carlos A. Labarrere
-
Publication number: 20180043016Abstract: Provided is a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B. The method may include periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.Type: ApplicationFiled: August 10, 2017Publication date: February 15, 2018Applicant: XTL Biopharmaceuticals Ltd.Inventors: Murray B. UROWITZ, David ISENBERG, Daniel WALLACE, Monique BEN-AM, Joshua LEVINE, Daphan PARAN
-
Publication number: 20180043017Abstract: Provided is a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 (“BILAG”) as category A (“BILAG A”) or at least two organ systems categorized as BILAG B. The method may include periodic administration to the human subject of one subcutaneous injection of 0.5 mg dose of Edratide every week, so as to treat the human subject.Type: ApplicationFiled: August 10, 2017Publication date: February 15, 2018Applicant: XTL Biopharmaceuticals Ltd.Inventors: Murray B. UROWITZ, David ISENBERG, Daniel WALLACE, Monique BEN-AM, Joshua LEVINE
-
Publication number: 20180043018Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: ApplicationFiled: October 5, 2017Publication date: February 15, 2018Inventors: Mark Manning, Robert W. Payne
-
Publication number: 20180043019Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: ApplicationFiled: October 5, 2017Publication date: February 15, 2018Inventors: Mark Manning, Robert W. Payne
-
Publication number: 20180043020Abstract: The present invention is directed to methods for reducing immunogenicity of a drug product, utilizing filling a container wherein the filled container has no headspace. The present invention is further directed to methods for stabilizing an aqueous drug substance solution by filling a container with the aqueous drug substance solution wherein the filled container has no headspace. The present invention is further directed to formulations of drug substances with reduced immunogenicity.Type: ApplicationFiled: October 25, 2017Publication date: February 15, 2018Inventors: John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning
-
Publication number: 20180043021Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating S. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.Type: ApplicationFiled: July 28, 2017Publication date: February 15, 2018Inventors: Edward M. Schwarz, Mark A. Sullivan, John L. Daiss
-
Publication number: 20180043022Abstract: The invention includes light-activated compositions and methods that are useful for promoting cell death or growth. In certain embodiments, the compositions comprise quantum dots (QD).Type: ApplicationFiled: March 18, 2016Publication date: February 15, 2018Inventors: PRASHANT NAGPAL, ANUSHREE CHATTERJEE, COLLEEN COURTNEY, SAMUEL MARTIN GOODMAN
-
Publication number: 20180043023Abstract: Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.Type: ApplicationFiled: August 23, 2017Publication date: February 15, 2018Applicant: Selecta Biosciences, Inc.Inventors: Petr Ilyinskii, Grayson B. Lipford, Charles Zepp
-
Publication number: 20180043024Abstract: Provided is an ophthalmic solution for treatment or prevention of lid wiper epitheliopathy, which is capable of imparting sufficient lubricity to a corneal surface or a soft contact lens surface. It has been found that the above-mentioned object can be achieved by an ophthalmic solution containing, at a specific ratio, a copolymer having a structure having three kinds of different constituent units at a specific ratio.Type: ApplicationFiled: March 2, 2016Publication date: February 15, 2018Applicant: NOF CORPORATIONInventors: Shunsuke Sakurai, Koji Miyamoto, Yoshihisa Shimamura, Masatomo Takahashi, Yosuke Matsuoka, Nobuyuki Yamamoto
-
Publication number: 20180043025Abstract: The invention generally relates to synthetic mimics of cell penetrating peptides. More particularly, the invention relates to certain novel monomers, oligomers and polymers (e.g., co-polymers) that are useful for the preparation of synthetic mimics of cell penetrating peptides, their compositions, preparations and use.Type: ApplicationFiled: August 22, 2017Publication date: February 15, 2018Inventors: Gregory N. Tew, Gregory J. Gabriel, Abhigyan Som, Arife Ozgul Tezgel
-
Publication number: 20180043026Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.Type: ApplicationFiled: December 17, 2015Publication date: February 15, 2018Applicant: DEXCEL PHARMA TECHNOLOGIES LTD.Inventors: Abraham J. DOMB, Michael GRISHKO, Ezra HANUKA, Ron SCHLINGER, Tal HAGIGIT
-
Publication number: 20180043027Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.Type: ApplicationFiled: October 23, 2017Publication date: February 15, 2018Applicant: EnGeneIC Molecular Delivery Pty LtdInventors: Himanshu BRAHMBHATT, Jennifer MACDIARMID
-
Publication number: 20180043028Abstract: The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.Type: ApplicationFiled: October 24, 2017Publication date: February 15, 2018Inventors: Sean M. Culbertson, Antoni Kozlowski, Tony Drew Vinson
-
Publication number: 20180043029Abstract: Polymeric carriers for the delivery of therapeutic agents and methods for making and using the same. The polymeric carriers include copolymers, diblock copolymers, polymeric architectures that include the copolymers and diblock copolymers, and particles assemblies comprising the copolymers, diblock copolymers, and polymeric architectures that include the copolymers.Type: ApplicationFiled: November 12, 2015Publication date: February 15, 2018Applicant: University of WashingtonInventors: Patrick S. Stayton, Anthony J. Convertine, Daniel M. Ratner, Debobrato Das, Selvi Srinivasan
-
Publication number: 20180043030Abstract: Provided are methods for linking polypeptides (including peptides and proteins) to other moieties using radical imitated thiol-ene chemistries, for example, modifying a polypeptide by introducing reactive thiol groups and reacting the thiol groups with olefin-containing reagents or alkyne-containing reagents under conditions that support radical thiol-ene or thiol-yne reactions. The reactive thiol groups have greater activity for radical thiol-ene reactions that a cysteine thiol group, including thiol groups that are separated from the peptide backbone by at least two carbon atoms, for example, the thiol group of a homocysteine residue. Also provided are compositions and biomaterials containing the linked polypeptides, for example, peptide and protein conjugates, and thiol-ene based biocompatible hydrogel polymers, and their uses in the medical field.Type: ApplicationFiled: February 9, 2016Publication date: February 15, 2018Inventors: Alexei V. KAZANTSEV, Peter D. MARINER, Martin STANTON
-
Publication number: 20180043031Abstract: The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy.Type: ApplicationFiled: August 28, 2017Publication date: February 15, 2018Inventors: Helen McCarthy, Aleksey Zholobenko, Ashley Davison, Tracy Robson
-
Publication number: 20180043032Abstract: The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated C. botulinum carrier complex is provided, where the carrier complex lacks a native neurotoxin subunit.Type: ApplicationFiled: October 9, 2017Publication date: February 15, 2018Inventors: Jennifer L. Ton, Ronald C. Bates, Ji Zheng, Phillip P. Nguyen, Timothy E. O'Neill
-
Publication number: 20180043033Abstract: The invention relates to conjugates comprising amatoxins and antibodies, in particular amatoxins linked to antibodies comprising specific cysteine residues.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Applicant: HEIDELBERG PHARMA GMBHInventors: Jan ANDERL, Torsten HECHLER, Christoph MÜLLER, Andreas PAHL
-
Publication number: 20180043034Abstract: The present invention relates to methods and compositions for gene therapy of retinitis pigmentosa related to mutations in pre-mRNA processing factor 31 (PRPF31).Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Inventors: Eric A. Pierce, Michael H. Farkas, Maria E. Sousa
-
Publication number: 20180043035Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: ApplicationFiled: March 11, 2016Publication date: February 15, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna, Tiansen Li
-
Publication number: 20180043036Abstract: Provided are modified lipid compounds and their use in the formation of lipid assemblies. Also provided are lipid assemblies including (a) an amphoteric lipid including in covalent association with (i) one or more acyl chains; (ii) one or more weak base moiety; (iii) one or more weak acid moiety; the lipid assembly also including (b) one or more additional lipids, at least one of which being a zwitterionic lipid. In some embodiments, the amphoteric lipid is a compound including (a) a tri-functional moiety; (b) two non-phosphate lipid chains associated with two of the functional moieties of said tri-functional moiety; (c) optionally a spacer moiety associated with the third of the functional moieties of said tri-functional moiety; and (d) a polyalkylamine optionally including a short peptide with one to several carboxylic acid residues. Further provided are the uses of the lipid assembly, inter alia, for transfection or cancer treatment.Type: ApplicationFiled: February 4, 2016Publication date: February 15, 2018Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., QBI Enterprises Ltd., Rosetta Genomics, Biolab Ltd.Inventors: Sharon AVKIN-NACHUM, Tirtsa KLEINMAN, Noga YERUSHALMI, Yechezkel BARENHOLZ, Rivka COHEN, Kirill MAKEDONSKI, Eylon YAVIN, Andreas Ingemann JENSEN, Keren TURJEMAN
-
TISSUE SPECIFIC MARKERS FOR PREOPERATIVE AND INTRAOPERATIVE LOCALIZATION AND VISUALIZATION OF TISSUE
Publication number: 20180043037Abstract: Surgeons may face the difficulty of preoperatively selecting the location for making an incision and intraoperatively identifying and differentiating targeted tissue for removal or for identification so that it is not removed along with neighboring or non-target tissue or so that neighboring or non-target tissue is not nicked, harmed, or removed accidentally. A tissue specific marker can include an aptamer or an affimer configured to bind to a pre-selected target tissue and one or more indicator elements coupled with the aptamer or the affimer. The one or more indicator elements produce a signal thereby allowing identification of the target tissue in a preoperative and operative manner.Type: ApplicationFiled: August 11, 2017Publication date: February 15, 2018Inventors: Dennise DALMA-WEISZHAUSZ, Alex VAYSER, James BREDENKAMP -
Publication number: 20180043038Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Provided are antibody/nanoparticle conjugates. Also provided are compositions and delivery agents that include the disclosed antibodies, conjugates, fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.Type: ApplicationFiled: October 2, 2017Publication date: February 15, 2018Inventors: Pinku Mukherjee, Juan Luis Vivero-Escoto
-
Publication number: 20180043039Abstract: Lipid-based nanoparticle compositions are provided. The compositions generally comprise lipid-hydrophilic polymer-amyloid binding ligand conjugates, and may be liposomal compositions. The compositions, including the liposomal compositions, may be useful for imaging and/or the treatment of amyloid-? plaque deposits characteristic of Alzheimer's Disease.Type: ApplicationFiled: October 30, 2017Publication date: February 15, 2018Inventors: Ananth V. Annapragada, Jason L. Eriksen, Eric A. Tanifum, Indrani Dasgupta, Stephen C. Cook
-
Publication number: 20180043040Abstract: The present disclosure provides a positron emission tomography (PET)-detectable 1-((2-fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine ([18F]DASA-23) probe that can selectively bind to the pyruvate kinase variant M2 (PKM2) found in cancer cells, such as of human glioma. Given the importance of PKM2 in the regulation of tumor metabolism, there is an on-going need to non-invasively measure its expression through the development of PKM2-specific radiopharmaceuticals. Precursors useful for the synthesis of the radiolabeled [18F]DASA-23-PKM2-specific probe and related compounds, and their methods of synthesis, are provided. Since the half-life of the 18F isotope is approximately 110 min, it is advantageous for a practitioner to attach the radionuclide to the precursor shortly before administration. Therefore, a precursor compound suitable for receiving the radionuclide and capable of specifically binding to the PKM2 variant can be provided.Type: ApplicationFiled: August 11, 2017Publication date: February 15, 2018Inventors: Corinne Gaye Beinat, Israt Shamima Alam, Michelle L. James, Sanjiv S. Gambhir, Ananth Srinivasan
-
Publication number: 20180043041Abstract: Methods of ex vivo labeling of a biological material for in vivo imaging, methods of labeling a biological material in vivo, methods for preparing a labeling agent, and methods for in vivo imaging of a subject using a biological material labeled with a labeling agent are disclosed. In one non-limiting example, the biological material is selected from cells and the labeling agent is a 89Zr-Desferrioxamine-NCS labeling agent.Type: ApplicationFiled: March 7, 2016Publication date: February 15, 2018Inventors: Aditya Bansal, Timothy R. DeGrado, Mukesh K. Pandey
-
Publication number: 20180043042Abstract: A pressurized phase for vapor treating a reusable metal keg includes filling the keg with pressurized water vapor through an inlet and then interrupting the connection, thus initiating a dwell time. During this dwell time, condensate forms on the inner surfaces of the keg. Meanwhile, one causes relative movement between the water vapor and the keg's inner walls.Type: ApplicationFiled: February 3, 2016Publication date: February 15, 2018Inventor: Hilmar FICKERT
-
Publication number: 20180043043Abstract: A portable capsule for insertion into a bandage consists of an light emitting diode (LED) connected to a power source encased in a housing. The housing has a clear window that allows the UV light from the LED to shine through and sterilize the surrounding bandage area. The capsule is inserted into the bandage material and held within the bandage to kill any bacteria that enters the bandage. The capsule is kept away from any direct skin contact, so there is no risk of burns or skin damage from the UV light. When the bandage is removed from the patient, the capsule can be removed from the bandage, cleaned, and re-used in the next bandage.Type: ApplicationFiled: October 4, 2016Publication date: February 15, 2018Inventor: Donald SPECTOR
-
Publication number: 20180043044Abstract: A disinfecting method includes irradiating fungi or bacteria with light including violet light having a light emission peak with (i) a full width at half maximum of at most 20 nm and (ii) a peak wavelength included in a range of from 380 nm to 410 nm, inclusive.Type: ApplicationFiled: August 2, 2017Publication date: February 15, 2018Applicant: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.Inventors: Yoshiaki HACHIYA, Kazushige SUGITA, Takashi MANIWA, Makoto YAMADA
-
Publication number: 20180043045Abstract: The invention relates to a method for reducing water consumption of a system (1) for processing a liquid or semi-liquid food product, after an interruption of said processing. The food product is a composition of a first sub-composition having a low concentration and a second sub-composition having a high concentration, wherein said high concentration is greater than said low concentration. The method comprising the steps of pushing said first sub-composition, said second sub-composition and said food product out of the system (1) using water until the system (1) substantially contains only water, sterilizing the system (1) by heating the water present in the system (1), and forming a new food product by adding a new second sub-composition to the sterile water, thereby using said sterile water as said first sub-composition.Type: ApplicationFiled: March 10, 2016Publication date: February 15, 2018Inventors: Pernilla Toft, Göran Stjernberg, Peter Jensinger
-
Publication number: 20180043046Abstract: Provided herein is a degassing valve for a dry consumer product (e.g., a dry oodstuff) that has a pleasant aroma. Such a valve includes a valve body, a one-way valve element positioned on the valve body, and, preferably, a filter associated with said valve body wherein the filter is configured to facilitate the passage of a gas. The gas may be selected from the group consisting of air, carbon dioxide, oxygen, nitrogen, and methane, or mixtures thereof. Additionally, the gas contains one or more aroma-conferring volatile molecule species responsible for the aroma characteristic of the product. The filter of the valve body may include activated charcoal, an activated charcoal mixture or a combination thereof. In some embodiments, the dry consumer product is a dry foodstuff such as flavored or seasoned breadcrumbs, spices, or other flavorful dry foods, the aroma(s) of which can provide an important marketing benefit.Type: ApplicationFiled: September 11, 2017Publication date: February 15, 2018Inventors: Nicole Marie DEVINE, Melissa SCORSONE
-
Publication number: 20180043047Abstract: Aspects of the disclosure include an attachment for providing a scent to a container. In some aspects, a scent delivery system includes a bottle including a collar and a ledge structure each extending circumferentially outward; a scent ring loaded with a volatile chemical agent to emanate and generate a scent and including an interior protruding structure projecting from an interior wall of the ring, the scent ring configured to fasten around the neck of the bottle based on contact between the interior protruding structure and the ledge structure of the bottle; and a cap reversibly attachable to the bottle and including an interior rim structure that circumferentially projects from the interior of the cap, where the cap is structured to enclose the scent ring in a compartment formed between the collar and the interior rim structure when the cap is securely fastened to the bottle and trap the scent.Type: ApplicationFiled: October 12, 2017Publication date: February 15, 2018Inventor: Shawn Griffis
-
Publication number: 20180043048Abstract: A fragrance dispenser unit has a piezoelectric discharge nozzle and a disposable snap-in air freshener containing aromatic liquid. The dispenser unit incorporates a battery power source and a piezoelectric driver circuit on a printed circuit board. The dispenser unit The cartridge includes a housing and an induction-sealed fragrance bottle that snaps into a socket at the bottom of the housing when the cartridge is to be activated. A membrane seal on the mouth of the bottle is pierced by a knife in the housing as the bottle is snapped into place. Liquid fragrance is directed to a micro-perforated vibratory plate in the piezoelectric nozzle by an airtight path that includes: first, a horizontal channel; second, a vertical wick; and, finally, a horizontal wick.Type: ApplicationFiled: July 27, 2017Publication date: February 15, 2018Inventors: Rami Sidawi, Asad Rahman
-
Publication number: 20180043049Abstract: A multifunctional polymer-free clay products having a clay, a zwitterion, a silver compound, and, an analgesic. The multifunctional polymer-free clay product provides antimicrobial and pain relieving properties. Method of treatment of burns using the multifunctional polymer-free clay product having antimicrobial and pain relieving properties. Methods of preparing multifunctional polymer-free clay products having a clay, a zwitterion, a silver compound, and, an analgesic.Type: ApplicationFiled: November 7, 2016Publication date: February 15, 2018Inventors: KRISHNASWAMY KASTHURI RANGAN, TIRUMALAI SRINIVAS SUDARSHAN
-
Publication number: 20180043050Abstract: Absorbent articles comprising a low cold flow construction adhesive suitable for joining at least two absorbent article components together, wherein the adhesive comprises an ethylene-based polyolefin resin and a crystallization enhancer, wherein at least one of the absorbent article components comprises a nonwoven material, and wherein the absorbent articles have an in-bag compression opening force of less than about 0.75N. Also, a method for assembling such articles.Type: ApplicationFiled: October 26, 2017Publication date: February 15, 2018Inventors: Jay TAO, Ebrahim REZAI
-
Publication number: 20180043051Abstract: A process for producing water-absorbing polymer particles by suspension polymerization, wherein the polymerization is conducted in the presence of dissolved oxygen.Type: ApplicationFiled: February 17, 2016Publication date: February 15, 2018Inventors: Tina Mark, Thomas Daniel, Stefan Molter, Erich Lutz
-
Publication number: 20180043052Abstract: The present invention relates to a process for producing surface-postcrosslinked water-absorbent polymer particles comprising polymerizing droplets of a monomer solution, wherein water-absorbent polymer particles having an average particle diameter from 420 to 700 ?m, an amount of water-absorbent polymer particles having a particle size of less than 300 ?m of less than 5% by weight and an amount of water-absorbent polymer particles having a particle size of more than 800 ?m of less than 5% by weight are coated with at least one surface-postcrosslinker and thermal surface-postcrosslinked.Type: ApplicationFiled: January 26, 2016Publication date: February 15, 2018Inventors: Stephan Bauer, Yvonne Hagen, Katrin Baumann, Christophe Bauduin, Thomas Daniel, Thomas Pfeiffer
-
Publication number: 20180043053Abstract: The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone.Type: ApplicationFiled: August 10, 2017Publication date: February 15, 2018Inventors: Morshed KHANDAKER, Shahram RIAHINEZHAD
-
Publication number: 20180043054Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.Type: ApplicationFiled: September 7, 2016Publication date: February 15, 2018Inventors: Shuang Chen, Yufu Li, Dengmin Feng, Xiang Wan
-
Publication number: 20180043055Abstract: A method of forming a fibrin hydrogel composition is described. The method comprises forming an aqueous solution comprising fibrinogen, fibrin-forming enzyme, and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt concentration is greater than or equal to the threshold concentration to form a fibrin hydrogel. The method further comprises reducing the salt concentration below the threshold concentration to form a fibrin hydrogel. In some embodiments, the aqueous solution further comprises a plasticizer. A fibrin composition is also described comprising a fibrin hydrogel having a fibrin concentration ranging from 0.1 to 10 wt-%; and a fibrin hydrogel forming salt. The fibrin hydrogel forming salt has a concentration less than a threshold concentration to form the fibrin hydrogel. The fibrin hydrogel or dehydrated fibrin hydrogel can be in various physical forms such a sheet, foam, or plurality of pieces.Type: ApplicationFiled: March 25, 2016Publication date: February 15, 2018Inventors: Jason W. Bjork, Alexi J Young, Raha A. Been, Jana Ninkovic, Bryan A. Baker
-
Publication number: 20180043056Abstract: A coating for a metal surface, the coating including poly(ethylene glycol) disposed on and covalently bonded directly to at least a portion of the metal surface, and a functional group grafted to at least a portion of the poly(ethylene glycol). The functional group is one of a bioactive functional group and an antimicrobial functional group.Type: ApplicationFiled: August 9, 2017Publication date: February 15, 2018Inventors: Danielle Frankson, Joseph T. Delaney, JR., David R. Wulfman, Adam McGraw, Sarah M. Gruba
-
Publication number: 20180043057Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction The manufacturing methods take advantage of a new recognition that bioactive gels from.Type: ApplicationFiled: October 2, 2017Publication date: February 15, 2018Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
-
Publication number: 20180043058Abstract: A heart valve leaflet including a thermoplastic polyurethane (TPU) mesh material that has a stiffness that is comparable to a native heart valve leaflet, such that it functionally mimics a native heart valve leaflet. The heart valve leaflets optionally include one to three layers of cells cultured on each side of the mesh material. Also disclosed is a heart valve including the heart valve leaflet and a frame.Type: ApplicationFiled: October 4, 2017Publication date: February 15, 2018Inventor: Arash Kheradvar
-
Publication number: 20180043059Abstract: Embodiments of the invention are directed to a vascular structure forming implant produced by additive manufactured Ti-6Al-4V foams a living implant.Type: ApplicationFiled: August 9, 2017Publication date: February 15, 2018Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Victor Rodriguez Correa, Lawrence E. Murr, Kristine Garza
-
Publication number: 20180043060Abstract: The invention relates to a method for coating a vascular endoprosthesis, wherein the outside of the vascular endoprosthesis is wetted at least partially with a first solution of an active substance, the vascular endoprosthesis is moved in a rotational movement about the longitudinal axis of the vascular endoprosthesis, and a radially acting mechanical force is applied to the outside of the vascular endoprosthesis. The rotational movement has the effect that the solution is carried outward by the centrifugal force, such that no active substance deposits in the interior of the vascular endoprosthesis. The application of a mechanical force to the outside of the vascular endoprosthesis then has the effect of creating crystallization nuclei, such that the active substance can crystallize out.Type: ApplicationFiled: October 25, 2017Publication date: February 15, 2018Applicants: Aachen Scientific International PTE. LTD.Inventor: Alexander Ruebben
-
Publication number: 20180043061Abstract: The present invention relates to: a porous polymer material having a porous structure over the entire polymer and having a dense porous structure in which pores are connected to each other therein. The porous polymer material is harmless to the human body as it does not use toxic organic solvents. In addition, a porous polymer material can be prepared without using any additives for forming pores and the particle size can be easily controlled, and thus a polymer material suitable for various uses can be prepared. Furthermore, the extended release of a loaded bioactive material is possible only by the dense porous structure of a polymer itself without using an additive and a surface modification method in the porous polymer material of the present invention. Therefore, the porous polymer material can be applied to a biodegradable material in various bio-fields requiring the extended release of a bioactive material.Type: ApplicationFiled: September 21, 2015Publication date: February 15, 2018Applicant: DANKOOK UNIVERSITY CHEONAN CAMPUS INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Han-a-reum Lee, Ho-yong Kim, Jin-hyun Park, June-ho Byun, Jin-ho Lee, Se-heang Oh
-
Publication number: 20180043062Abstract: An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.Type: ApplicationFiled: March 18, 2016Publication date: February 15, 2018Inventors: Yunzhi Yang, Stuart B. Goodman, Yaser Shanjani
-
Publication number: 20180043063Abstract: The present disclosure relates to a multilayer coatings that include a hydrophobic encasing layer and allow controlled release of a water soluble drug. The encasing layer encases water soluble, or hydrophilic, drugs with a flexible layer and comes in good intimate contact with the water soluble drug layer. Thus, the encasing layer conforms to the water soluble drug and can control the release of the drug. Advantageously, major cuts or fissures in the coating do not cause the water soluble drug to leak or burst out; rather, the encasing layer continues to provide modulated release of the drug. The present disclosure also includes methods of making the coating, methods of using the coating, and articles that include the coating.Type: ApplicationFiled: October 11, 2017Publication date: February 15, 2018Inventors: Kristin Taton, Laurie Lawin, Patrick Guire